Trump administration indefinitely delayed BALANCE, a Medicare pilot to expand GLP-1 weight-loss drug coverage through private insurers, Axios reports
- Medicare will instead cover the drugs through a transitional programme from July until the end of 2027
- UnitedHealth (UNH), Eli Lilly (LLY), Novo Nordisk (NOVOB DC) and AHIP were cited around insurer concerns, beneficiary access and next steps
Context
The indefinite delay of the BALANCE Medicare pilot program impacts the coverage of GLP-1 weight-loss drugs, reflected through a transitional program instead. This could create uncertainty for insurers like UnitedHealth and pharmaceutical companies such as Eli Lilly and Novo Nordisk regarding revenue projections and market access. The regulatory landscape here may influence broader health care funding and investment strategies across the sector.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#ELI LILLY & CO#LLY.US#UNITEDHEALTH GROUP INC#UNH.US#NOVO NORDISK A/S#NOVOB.DC#FOREX#EQUITIES#ENERGY#EU SESSION#WTI#COMMODITIES#MANAGED HEALTH CARE#PHARMACEUTICALS#HEALTH CARE PROVIDERS & SERVICES#PHARMACEUTICALS (GROUP)#HEALTH CARE EQUIPMENT & SERVICES (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#UNH#DXY#TRUMP#US EQUITIES